InflaRx announced today the successful completion of its recent clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation. The trial reached its anticipated endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
"Completing a successful clinical phase I trial with IFX-1 within our first financing round and in less than 4 years development represents a major milestone for us" says Prof. Niels Riedemann, co-founder and CEO of InflaRx. - IFX-1 is a first-in-class new monoclonal antibody which was designed to control a key mechanism driving inflammation. "We have spent many years of planning and preparing for this technically challenging development of IFX-1 and we are very happy that we were able to generate an antibody with such large potential in the inflammatory disease areas" explains Prof. Renfeng Guo, co-founder and CSO of InflaRx.
IFX-1 was designed primarily to control the inflammatory response in acute diseases, lead by the sepsis indication. The company is currently extending development of this technology into other inflammatory indications - "Our strategic positioning in Jena, with our strong clinical ties to the sepsis and intensive care world, puts us in a unique position to tackle the challenges of the clinical development of IFX-1" ads Prof. Riedemann.
InflaRx started its operating business in 2008 and was financed with three milestones-driven tranches within its series A, lead by Affentranger Associates alongside with bm-t (beteiligungsmanagement thüringen gmbh). "Applying a global development approach with a highly skilled team in Jena, InflaRx has delivered a very cost-effective and fast value creation" says Nicolas Fulpius, board chairman of InflaRx and Partner at Affentranger Associates.
Study shows potential for universal flu vaccine with broad antibody response